HIV just got dethroned. What was once a death sentence is now something millions live with — quietly, normally, for decades. Modern antiretroviral therapy has flipped the script. People diagnosed today, who take their meds consistently, can expect a near-normal lifespan. The virus stays buried. Undetectable. Untransmittable. Let that sink in. A diagnosis that wiped out a generation in the 80s and 90s is now a manageable condition — closer to diabetes than to doom. And the science isn't stopping there. Gilead's once-daily single-tablet BIC/LEN regimen is under FDA priority review with a decision expected August 27, 2026. One pill. Once a day. That's it. At CROI 2026 in Denver, the RIO cure trial showed over half of participants kept their viral load undetectable for more than 20 weeks after stopping treatment entirely. Two have been off meds for over a year. A 62-year-old Canadian man — now known as the Toronto patient — was announced likely cured in April 2026 after a stem cell transplant. Yale researchers cracked open a hidden mechanism called circHIV that could become the next major drug target. Case Western turned the immune system's own Natural Killer cells into HIV-hunting weapons. Oxford is using broadly neutralising antibodies to keep the virus in check long after pills are gone. The hunt for a full, scalable cure is no longer science fiction. It's a research pipeline with real names, real patients, and real timelines. HIV used to mean counting the years you had left. Now it means living them. Source: Aidsmap (CROI 2026), Gilead Sciences, amfAR, Weill Cornell Medicine, Yale News, Case Western Reserve University

🇰🇪 🇺🇸 HIV deaths on the rise in Kenya since US aid cuts At least 24 HIV-positive sex workers in Kenya have died since aid was slashed by the United States in early 2025, despite being in good health until then. The US has long been the biggest donor to Kenya's health system, but the Trump administration has restructured support away from NGOs, and passed rules to prevent them promoting issues it opposes

GRINDR TO BUY HIV-PREVENTION TELEHEALTH PROVIDER FREDDIE FOR $250M $GRND agreed to acquire Freddie parent PurposeMed for $190M in cash and $60M in stock, marking its first major acquisition. Freddie focuses on HIV-prevention telehealth, including access to PrEP, and will be combined with Grindr’s existing Woodwork telehealth business under a new Grindr Health offering. Grindr plans to focus on expanding Freddie in the U.S., where it sees roughly a $240M annual revenue opportunity based on 50,000 patients. The company says the deal should be immediately accretive to EBITDA, though margins could initially be pressured as it invests in growth. PurposeMed could also receive up to another $70M if it hits 2027 performance targets. The deal is expected to close in Q4. Source: WSJ

🚨 UGANDA: Experts warn HIV prevention injection is NOT a vaccine Lenacapavir (twice-yearly injection) is a prevention tool, not a vaccine. Those who received the first dose must take the second on schedule to maintain protection. Uganda aims to cut 37,000 new infections yearly to under 10,000 by 2030, but compliance is critical. Supply shortages and high cost ($28,000 per dose) remain major challenges. Government relies on donations. Experts urge continued use of condoms, PrEP tablets, and other proven methods alongside the injection. High demand has already stretched limited stocks.